Clinical Trial of BAO-G Technique in Complex Aortic Aneurysm Endovascular Repair (BAO-G-02)

Inclusion Criteria: 1. Diagnosed with Crawford type Ⅰ- Ⅴ thoracoabdominal aortic aneurysm or complex abdominal aortic aneurysm, with a healthy proximal landing zone (\>20mm length, angulation \<60°) in the descending aorta and maximum aneurysm diameter ≥4cm 2. Patients with pseudoaneurysms, post-dissection aneurysmal degeneration, or failure of previous EVAR were also eligible if the pathology involved the visceral aortic segment; 3. Scheduled for endovascular aortic repair with commercially available iliac branch devices for visceral artery reconstruction 4. Signed informed consent and committed to protocol-defined follow-up Exclusion Criteria: 1. Acquired language barrier, intellectual decline, cognitive impairment, or mental illness preventing informed consent 2. Uncontrolled autoimmune diseases (e.g., Takayasu arteritis, systemic lupus erythematosus, vasculitis) 3. End-stage renal/hepatic/cardiac/pulmonary failure or malignancy diagnosed within 5 years, likely to cause mortality during follow-up 4. Active bleeding or coagulopathy within 6 months (high bleeding risk) 5. Uncontrolled hypertension (resting SBP \>180 mmHg or DBP \>110 mmHg) 6. Uncontrolled diabetes (fasting blood glucose \>16.7 mmol/L) 7. Severe hepatic/renal dysfunction (serum creatinine \>3 mg/dL, ALT/AST \>3×ULN) 8. Concurrent participation in other interventional clinical trials 9. Pregnancy or perinatal status 10. Refusal to sign informed consent